Articles By Estel Grace Masangkay
-
Roche Buys Biotech Firm Dutalys And Bina Technologies
12/26/2014
Roche announced that it has entered into agreement to acquire Vienna-based, private biotech firm Dutalys and its proprietary DutaMab technology for the discovery and development of fully human, bi-specific antibodies.
-
Novartis Links With BiolineRX To Develop Israel-Made Drugs
12/26/2014
Israeli clinical-stage biopharmaceutical company BioLineRX announced that it has signed up Swiss pharma giant Novartis in a multi-year strategic collaboration to develop and commercialize Israeli-sourced drug candidates.
-
Merck Acquires OncoEthix, Cancer Drug Lead
12/23/2014
Merck announced that it has acquired Swiss-based oncology firm OncoEthix through a subsidiary. The acquisition gives Merck access to an investigational drug in development for the treatment of blood malignancies and late-stage solid tumors.
-
GSK's Phase 3 Study For Shingles Vaccine Hits Endpoint
12/23/2014
GlaxoSmithKline announced positive results from its pivotal Phase 3 study investigating its vaccine HZ/su for the prevention of shingles.
-
TxCell Wins EU Orphan Designation For Col-Treg In Uveitis
12/22/2014
Biotech firm TxCell announced that it has received orphan drug designation from the European Commission for its investigational immunotherapy Col-Treg intended for eye disease autoimmune uveitis.
-
Alcon's Xtoro For “Swimmer's Ear” Gets FDA Green Light
12/22/2014
Novartis company, Alcon Laboratories, has received approval from the U.S. Food and Drug Administration (FDA) for its drug Xtoro (finafloxacin otic suspension) as treatment for acute otitis externa, also known as “swimmer’s ear.”
-
CMC Biologics, OncoSynergy To Co-Develop Ebola Drug Lead
12/18/2014
CMC Biologics announced that it has entered into agreement with OncoSynergy for accelerated process development and Good Manufacturing Practices (GMP) production for the investigational drug OS2966 targeting the Ebola virus.
-
AstraZeneca Posts Positive Data For Faslodex In Breast Cancer
12/18/2014
AstraZeneca presented new data for its investigational drug Faslodex (fulvestrant) as treatment for hormone-receptor positive breast cancer compared to Arimidex (anastrozole) at the recent 2014 San Antonio Breast Cancer Symposium (SABCS).
-
Alkermes Begins Phase 1 Trial For Schizophrenia Drug
12/18/2014
Alkermes announced that it has started a Phase 1 study to investigate extended dosing intervals of aripiprazole lauroxil as treatment for schizophrenia.
-
Pfizer To Develop GHD Drug With OPKO Health
12/18/2014
Pfizer announced it has partnered with Miami-based OPKO Health to develop the latter's long-acting hGH-CTP as treatment for growth hormone deficiency (GHD) syndrome in both adults and children, as well as for growth failure in children born small for gestational age (SGA) who fall short of catch-up growth standard by 2 years old.